Description
List of Contributors Preface PART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENT Chapter 1. Anticancer Drug Development: An Introduction by Edward A. Sausville, MD, PhD Chapter 2. Pharmacogenomics by Milly Graveno, PharmD, BCOP Chapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy, MD, Richard F. Little, MD, and Joshua F. Zeidner, MD Chapter 4. Drug Development and Regulatory Considerations by Vicky Hsu, PhD, Matthew D. Thompson, PhD, MPH, Donna Przepiorka, MD, PhD, and Olanrewaju O. Okusanya, Pharm.D., MS PART 2. CLASSICAL CYTOTOXIC AGENTS Chapter 5. Alkylating Agents by Ashkan Emadi, MD, PhD and Edward A. Sausville, MD, PhD Chapter 6. Pyrimidine- and Purine-based Antimetabolites, Hydroxyurea, Asparaginases by Ashkan Emadi, MD, PhD and Judith E. Karp, MD Chapter 7. Antimetabolites: Antifolates by Justin Lawson, PharmD, BCOP Chapter 8. Antimitotics by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhD PART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYS Chapter 9. DNA Repair, Apoptotic Pathways, and CDK Inhibitors by Mira A. Kohorst, MD and Scott H. Kaufmann, MD, PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca, MD and Lukasz P. Gondek, MD, PhD Chapter 11. Differentiating Agents and Microenvironment by Yuya Nagai, MD, PhD and Gabriel Ghiaur, MD, PhD PART 4. ORGAN-TARGETED APPROACHES Chapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu, MD and Ashkan Emadi, MD, PhD Chapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton, PhD and Katherine H. R. Tkaczuk, MD Chapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar, PhD, and Arif Hussain, MD Chapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples, PharmD, BCOP and Sagar Lonial, MD PART 5. IMMUNE-TARGETED STRATEGIES Chapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic, MD Chapter 17. Monoclonal Antibodies Including Immunoconjugates, Antibody-Drug Conjugates, and Cytokine-Directed Agents by Alison Duffy, PharmD, BCOP and Ciera Bernhardi, PharmD, BCOP Chapter 18. Immunotherapeutics: Checkpoint Inhibitors, Vaccines, Bispecifics, and CAR-T by Mark Yarchoan, MD and Elizabeth Jaffee, MD Index
Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland. Judith E. Karp, MD is Professor Emerita of Oncology and Medicine at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, in Baltimore, Maryland.